Clinical Studies
Our clinical studies are designed to characterize the safety, pharmacology, biological activity, and clinical potential of our investigational NLRP3 inhibitors.
REVEAL-PAD (Real-world Evaluation of Vascular Events and Limb Outcomes in Peripheral Artery Disease) is a prospective, multi-center observational study sponsored by Rezera and led by a steering committee of scientists and investigators from CPC Clinical Research, Duke Clinical Research Institute (DCRI) and Rezera. The study plans to investigate the role of inflammation in peripheral artery disease and to identify patients who could potentially qualify for upcoming clinical trials addressing residual inflammatory risk.
For more information, please contact [email protected].
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NT-0796 as an Adjunct to a Reduced Calorie Diet and Increased Physical Activity in Obese Participants With/Without Type 2 Diabetes over a 24 week treatment period.
For more information, please visit clinicaltrials.gov (NCT07055516).
A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 32 week treatment period.
For more information, please visit clinicaltrials.gov (NCT07220629).
A study investigating the safety, absorption, and elimination of NT-0150, a new compound that may potentially be used in the treatment of brain disorders.
For more information, please visit NL-OMON60655.